LGM Pharma Expands Analytical Services
The company is investing more than $2 million in its analytical testing services and adding suppository manufacturing capabilities.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
LGM Pharma, a contract development and manufacturing organization (CDMO), announced on March 13, 2024 that it is investing more than $2 million in its analytical testing services and expanding offerings by 50%. The company is also adding suppository manufacturing capabilities and expanding its facility in Rosenburg, Texas. These enhancements will offer the company’s customers streamlined, comprehensive manufacturing.
The addition of suppository drug delivery systems to its Rosenburg facility comes as the delivery system gains traction in the industry. According to the company, “Suppository drug delivery systems enable more direct and efficient drug absorption for precise drug release kinetics, including for high medication concentrations and extended drug release times. They provide an excellent solution for patients with difficulty swallowing pills or those experiencing nausea, as well as for chronic conditions and women’s health.”
Ian Gibson, executive vice president of operations at LGM Pharma, stated in a company press release, “As patient needs become increasingly diversified, the pharmaceutical industry needs CDMO partners that can provide specialized capabilities. Our expertise in suppository formulation development and manufacturing, including the most advanced delivery systems, represents another example of our dedication to providing strategic solutions to our industry partners.”
The CDMO’s analytical testing services include method development, validation services, and stability testing. The company’s Irvine, Calif., facility offers chromatography and spectroscopy instrumentation. In addition, the company provides API sourcing and procurement, formulation development, and raw material and finished product testing and packaging.
“Offering standalone analytical testing expands our agility and capacity to serve as a strategic resource for our pharmaceutical partners, providing them with flexibility to meet the precise needs of their expanding product portfolios,” said Prasad Raje, CEO at LGM Pharma, in the release. “With our continuum of robust and tailored support services, we enable pharmaceutical companies to get to market faster and achieve sustainable success in today’s complex market.”
“We take a rigorous, multi-disciplinary approach to address our customers’ most complex analytical needs,” said Shailesh Vengurlekar, senior vice-president of Quality and Regulatory Affairs at LGM Pharma, in the press release. "Our team consists of more than 60 quality and analytical specialists who have decades of experience in all aspects of analytical testing, method development, and validation.”
LGM Pharma will be showcasing its ATS and CDMO services at 2024 DCAT Week, March 18–21, in New York City.
Source: LGM Pharma
